Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Key Inclusion Criteria: * Aged \> 18 years to 70 years inclusive in Cohort 1; aged ≥ 45 to 70 years inclusive in Cohorts 2-4, aged 18 to 80 years inclusive in Cohort 5. * For subjects in Cohort 1, IOP between 12 and 23 mm Hg (inclusive). For subjects in Cohorts 2-4, IOP between 16 and 23mm Hg (inclusive). For subjects in Cohort 5, IOP between 17 and 27 mm Hg (inclusive). * Central corneal thickness of 480 to 600 μm, inclusive * For subjects in Cohort 5, diagnosis of OAG or OHT * For subjects in Cohort 5, currently receiving prostaglandin therapy for IOP lowering Key Exclusion Criteria: * Diagnosis of any form of glaucoma in Cohorts 1-4 * Clinically significant eye trauma within 6 months of screening * Any intraocular ophthalmic procedure within 6 months of screening * Any ocular inflammation within 90 days of screening or a history of recurrent uveitis in either eye * Subjects with any known chronic ocular disease (other than incipient cataract or refractive error) * Any condition preventing valid applanation tonometry measurement, e.g., clinically significant corneal disease, refractive surgery * Visual acuity (VA) worse than 20/30 in either eye, For Cohort 5 VA worse than 20/100 in either eye